# | Filing Date | Period End Date | Type | Report Link |
---|---|---|---|---|
No Data found |
# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
Company's common stock will begin trading on the Nasdaq Global Select Market under the new ticker symbol "ZVRA" sta...
Interim data analysis of four-year, open-label extension from Phase 2/3 clinical trial suggests arimoclomol may reduce long-ter...
KemPharm, Inc. (NasdaqGS: KMPH) today announced that Richard W. Pascoe, Chief Executive Officer of KemPharm, has issued a Lett...
Upgrades